| 名稱 | Bitopertin |
| 描述 | Bitopertin (Paliflutine) (RG1678, RO-4917838) is a potent inhibitor of glycine transporter 1 (GlyT1), with Ki of 8.1 nM for human hGlyT1b and IC50 of 22-25 nM in Chinese hamster ovary cells. |
| 激酶實驗 | Association and dissociation kinetic analysis of [3H]ORG24598 to hGlyT1 and ratforebrain membranes is performed. [3H]ORG24598 binding experiments are performed using membranes from CHO cells expressing hGlyT1b and also in membranes from mouse, rat, monkey, and dogforebrains. Saturation isotherms are determined by adding [3H]ORG24598 to rat, mouse, monkey, and dog forebrain membranes (40 μg/well) and cell membranes (10 μg/well) in a total volume of 500 μL for 3 h at room temperature. Saturation binding experiments are analyzed by an Excel-based curve-fitting program using the Michaelis-Menten equation derived from the equation of a bimolecular reaction and the law of mass action:B=(Bmax×[F])/(Kd+[F]), where B is the amount of ligand bound at equilibrium, Bmax the maximum number of binding sites, [F] the concentration of free ligand, and Kd the ligand dissociation constant. For inhibition experiments, membranes are incubated with 3 nM [3H]ORG24598 and 10 concentrations of Bitopertin for 1 h at room temperature. Schild analysis is performed in the presence of increasing concentrations of [3H]ORG24598 (1-300 nM). IC50 values are derived as described above. Ki values are calculated according to the following equation: Ki=IC50/(1+[L]/Kd)[1]. |
| 動物實驗 | Bitopertin (RG1678) is dissolved in H2O with 0.3% Tween 80 (Mice)[1]. Bitopertin (RG1678) is prepared in Polysorbate 80, HEC, Methyl- and Propylparaben pH 6.0 (Rats)[1].Male NMRI mice (20-30 g) are treated with Bitopertin (0.3, 3, 1, and 10 mg/kg p.o.) or vehicle (p.o.). After 1 min, L-687,414 (50 mg/kg s.c.) or vehicle is given. After 15 min of habituation in the activity chambers, horizontal activity is recorded for 60 min. The time course of Bitopertin effects on L-678,414-induced hyperactivity is also examined; locomotor activity is assessed 2.5, 4.5, and 24 h after administration of Bitopertin (L-678,414 is always given 15 min before the activity procedure). In addition, the effect of subchronic Bitopertin is investigated. Mice receive vehicle or Bitopertin (1 mg/kg p.o.) for 4 consecutive days and L-678,414-induced hyperactivity is evaluated on day 5. Wistar rats receive a 14-day treatment of PCP HC1 (5 mg/kg) or vehicle (NaCl 0.9%, 5 mL/kg i.p.). 24 h following the last injection, rats (6-18 per group) are allowed to individually habituate to the test boxes for 30 min. Rats then received Bitopertin (1, 3, 10 mg/kg p.o.) or vehicle (Polysorbate 80, HEC, Methyl- and Propylparaben pH 6.0; 5 mL/kg p.o.), followed after 1 h by 1 mg/kg D-amphetamine or vehicle i.p. Horizontal activity is recorded directly after the administration of Bitopertin until 120 min after dosing with amphetamine. Data are analyzed by ANOVA supplemented by Fischer's least significant difference post hoc test. |
| 體外活性 | RG1678在穩(wěn)定表達hGlyT1b和mGlyT1b的細胞中非競爭性抑制[3H]甘氨酸的攝取，其IC50值分別為25 ± 2 nM和22 ± 5 nM（n = 6），并在來自中國倉鼠卵巢細胞的膜上以8.1 nM的Ki值競爭性置換[3H]ORG24598的結合，針對human hGlyT1b。至30 μM濃度，RG1678對hGlyT2介導的[3H]甘氨酸攝取無影響?；谥脫Q[3H]ORG24598的能力，RG1678的藥理學在不同物種之間沒有顯著差異。在海馬CA1錐體細胞中，RG1678在30 nM（213 ± 18%；n=7）、100 nM（269 ± 44%，n=13）時增強NMDA依賴的長期增強效應（LTP），但在300 nM（152 ± 14%；n=9）時則沒有這種效果。 |
| 體內活性 | 給予RG1678后，在大鼠的微透析實驗和大鼠的腦脊液(CSF)中均可觀察到持續(xù)時間超過3小時的劑量依賴性胞外甘氨酸水平增加。在小鼠中，RG1678劑量依賴性且顯著地減輕了由精神興奮劑D-安非他明引起的過度活動。此外，RG1678還能阻止長期用苯環(huán)已哌啶（一種NMDA受體開放通道阻斷劑）處理的大鼠對D-安非他明挑戰(zhàn)的過度反應[1]。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 50 mg/mL (92 mM)
H2O : Insoluble
Ethanol : 5 mg/mL
|
| 關鍵字 | inhibit | Bitopertin | GlyT | Inhibitor | RO 4917838 | RG-1678 | RG 1678 | Glycine transporters | RO-4917838 |
| 相關產品 | Opiranserin | ALX-1393 | Bitopertin (R enantiomer) | Org 25543 hydrochloride | Opiranserin hydrochloride | PF-03463275 | Tilapertin | Amoxapine | Sarcosine | Iclepertin | ASP2535 | LY2365109 hydrochloride |
| 相關庫 | 抑制劑庫 | 經典已知活性庫 | 已知活性化合物庫 | NO PAINS 化合物庫 | 神經退行性疾病化合物庫 | 藥物功能重定位化合物庫 | 人代謝物化合物庫 |